CoChat

Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes

Linnekamp, Janneke F., Wang, Xin, Medema, Jan Paul, Vermeulen, Louis · 2015 · Cancer Research
Cited by 202

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Personalized cancer medicine is becoming increasingly important in colorectal cancer treatment. Especially for targeted therapies, large variations between individual treatment responses exist. Predicting therapy response is of utmost significance, as it prevents overtreatment and adverse effects in patients. For EGFR-targeted therapy, many mechanisms of resistance have been uncovered, for example, mutations in KRAS and BRAF, and upregulation of alternative receptors. Currently, routine testing for all known modifiers of response is unpractical, and as a result, decision-making for anti-EGFR therapy is still largely based on assessing the mutation status of an individual gene (KRAS). Recently, comprehensive classifications of colorectal cancer have been presented that integrate many of the (epi-)genetic and microenvironmental factors that contribute to colorectal cancer heterogeneity. These classification systems are not only of prognostic value but also predict therapy efficacy, including the response to anti-EGFR agents. Therefore, molecular subtype–based stratification to guide therapeutic decisions is a promising new strategy that might overcome the shortcomings of single gene testing in colorectal cancer as well as in other malignancies. Furthermore, the development of new agents in a disease subtype–specific fashion has the potential to transform drug-discovery studies and generate novel, more effective therapies. Cancer Res; 75(2); 245–9. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-14-2240

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 24

  1. De Roock, 2011, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, Urol Oncol, 12, 594
  2. Scartozzi, 2011, Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients, Br J Cancer, 104, 1786, 10.1038/bjc.2011.161 · DOI
  3. Schlicker, 2012, Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines, BMC Med Genomics, 5, 66, 10.1186/1755-8794-5-66 · DOI · Paper page
  4. Perez-Villamil, 2012, Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior, BMC Cancer, 12, 260, 10.1186/1471-2407-12-260 · DOI · Paper page
  5. Budinska, 2013, Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer, J Pathol, 231, 63, 10.1002/path.4212 · DOI · Paper page
  6. Roepman, 2014, Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition, Int J Cancer, 134, 552, 10.1002/ijc.28387 · DOI · Paper page
  7. Marisa, 2013, Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value, PLoS Med, 10, e1001453, 10.1371/journal.pmed.1001453 · DOI · Paper page
  8. Sadanandam, 2013, A colorectal cancer classification system that associates cellular phenotype and responses to therapy, Nat Med, 19, 619, 10.1038/nm.3175 · DOI · Paper page
  9. Walther, 2009, Genetic prognostic and predictive markers in colorectal cancer, Nat Rev Cancer, 9, 489, 10.1038/nrc2645 · DOI · Paper page
  10. Malesci, 2007, Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer, Clin Cancer Res, 13, 3831, 10.1158/1078-0432.CCR-07-0366 · DOI · Paper page
  11. Abulí, 2013, Genetic susceptibility variants associated with colorectal cancer prognosis, Carcinogenesis, 34, 2286, 10.1093/carcin/bgt179 · DOI
  12. Tosolini, 2011, Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer Res, 71, 1263, 10.1158/0008-5472.CAN-10-2907 · DOI · Paper page
  13. Iida, 2013, Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment, Science, 342, 967, 10.1126/science.1240527 · DOI · Paper page
  14. Jawad, 2011, Inflammatory bowel disease and colon cancer, Recent Results Cancer Res, 185, 99, 10.1007/978-3-642-03503-6_6 · DOI
  15. Visvader, 2011, Cells of origin in cancer, Nature, 469, 314, 10.1038/nature09781 · DOI · Paper page
  16. Takahashi, 2014, Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer, Br J Cancer, 110, 2716, 10.1038/bjc.2014.230 · DOI
  17. Scartozzi, 2010, Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan, Int J Cancer, 1947, 1941, 10.1002/ijc.25193 · DOI · Paper page
  18. Wang, 2013, Dissecting cancer heterogeneity–an unsupervised classification approach, Int J Biochem Cell Biol, 45, 2574, 10.1016/j.biocel.2013.08.014 · DOI
  19. Sadanandam, 2014, Reconciliation of classification systems defining molecular subtypes of colorectal cancer -Interrelationships and clinical implications, Cell Cycle, 13, 353, 10.4161/cc.27769 · DOI · Paper page
  20. Chen, 2014, Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance, Mol Oncol, 1
  21. Nahta, 2006, Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer, Nat Clin Pract Oncol, 3, 269, 10.1038/ncponc0509 · DOI · Paper page
  22. Ithimakin, 2013, HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab, Cancer Res, 73, 1635, 10.1158/0008-5472.CAN-12-3349 · DOI · Paper page
  23. Creighton, 2013, Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors, PLoS ONE, 8, e71158, 10.1371/journal.pone.0071158 · doi:10.1371/journal.pone.0071158
  24. Collisson, 2011, Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy, Nat Med, 17, 500, 10.1038/nm.2344 · DOI · Paper page

Cited by

See all 202

Metadata

Authors
Linnekamp, J. F., Wang, X., Medema, J. P., & Vermeulen, L.
Venue
Cancer Research
Published
2015-01-14
Volume
75
Issue
2
Pages
245-249
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2058145479
Cited by
202
References
13
FWCI
10.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-2240
The paper
Linnekamp, J. F., Wang, X., Medema, J. P., & Vermeulen, L. (2015). Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-2240

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.